Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA inact mut |
| Therapy | Aspirin |
| Indication/Tumor Type | rectum cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA inact mut | rectum cancer | sensitive | Aspirin | Guideline | Actionable | Aspirin is included in guidelines as adjuvant therapy (category 2A) for patients with advanced rectal cancer harboring PIK3CA mutations, including hotspot mutations in exon 10 (reported as exon 9) and exon 21 (reported as exon 20), and other somatic mutations affecting the PI3K pathway genes PIK3R1 or PTEN (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... |